GC Wealth Management RIA’s Novo Nordisk NVO Stock Holding History

GC Wealth Management RIA’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.9M	Buy	39,641 +11,001	+38%	+$473K	0.11%	153
2026 Q1	$1.05M	Buy	28,640 +3,107	+12%	+$147K	0.04%	233
2025 Q4	$1.3M	Buy	25,533 +5,266	+26%	+$269K	0.05%	204
2025 Q3	$1.12M	Buy	20,267 +6,335	+45%	+$371K	0.04%	299
2025 Q2	$962K	Buy	13,932 +4,489	+48%	+$305K	0.08%	209
2025 Q1	$656K	Sell	9,443 -5,549	-37%	-$458K	0.12%	153
2024 Q4	$1.29M	Sell	14,992 -697	-4%	-$75.4K	0.23%	89
2024 Q3	$1.87M	Buy	15,689 +740	+5%	+$98.7K	0.33%	67
2024 Q2	$2.13M	Buy	14,949 +55	+0.4%	+$7.29K	0.42%	52
2024 Q1	$1.91M	Buy	14,894 +971	+7%	+$116K	0.38%	54
2023 Q4	$1.44M	Buy	+13,923	New	+$1.38M	0.65%	40

Other funds holding NVO

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

GC Wealth Management RIA's NVO Position: Q2 2026 in Review

GC Wealth Management RIA increased its Novo Nordisk (NVO) stake by 38% in Q2 2026, buying an estimated $473K and bringing the position to 39,641 shares worth $1.9M. The position accounts for 0.11% of the portfolio, ranked #153.

GC Wealth Management RIA first reported a position in NVO in Q4 2023 and has held it in 11 quarters since. The position peaked at $2.13M in Q2 2024. 1,350 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

GC Wealth Management RIA held 39,641 shares of Novo Nordisk worth $1.9M as of Q2 2026.
GC Wealth Management RIA bought 11,001 Novo Nordisk shares in Q2 2026, an estimated $473K.
Novo Nordisk made up 0.11% of GC Wealth Management RIA's portfolio in Q2 2026, its #153 holding.
GC Wealth Management RIA first reported a position in Novo Nordisk in Q4 2023 and has held it in 11 quarters since.
GC Wealth Management RIA's Novo Nordisk position peaked at $2.13M in Q2 2024.
1,350 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on GC Wealth Management RIA's 13F filing for Q2 2026, filed 16 Jul 2026.